Keywords: actelion, tracleer, meets, ph, iii, endpoint, swiss
Actelion's Tracleer meets Ph III endpoint
Article | 15 August 2005
Swiss drugmaker Actelion says that the preliminary results of a double-blind, placebo-controlled, randomized, multicenter, 190-patient Phase III study with its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
